Novavax Inc

NVAXNASDAQUSD
7.97 USD
0.27 (3.51%)AT CLOSE (11:59 AM EDT)
7.96
0.02 (0.19%)
POST MARKET (AS OF 04:52 PM EDT)
Post Market
AS OF 04:52 PM EDT
7.96
0.02 (0.19%)
🟢Market: OPEN
Open?$7.78
High?$8.14
Low?$7.77
Prev. Close?$7.70
Volume?2.8M
Avg. Volume?5.0M
VWAP?$7.96
Rel. Volume?0.56x
Bid / Ask
Bid?$6.85 × 100
Ask?$9.14 × 100
Spread?$2.29
Midpoint?$8.00
Valuation & Ratios
Market Cap?1.3B
Shares Out?162.9M
Float?154.7M
Float %?94.9%
P/E Ratio?2.85
P/B Ratio?-9.82
EPS?$2.70
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.35Strong
Quick Ratio?2.32Strong
Cash Ratio?0.58Adequate
Debt/Equity?-1.95Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
2.9CHEAP
P/B?
-9.82CHEAP
P/S?
1.12CHEAP
P/FCF?
N/A
EV/EBITDA?
2.2CHEAP
EV/Sales?
1.12CHEAP
Returns & Efficiency
ROE?
-344.7%WEAK
ROA?
37.4%STRONG
Cash Flow & Enterprise
FCF?$-251023000
Enterprise Value?$1.3B
Related Companies
Loading...
News
Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Employees
749
Market Cap
1.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
1995-12-05
Address
21 FIRSTFIELD RD
GAITHERSBURG, MD
Phone: 240-268-2000